Professional Documents
Culture Documents
Samantha Concepcion
Melissa Sirolli
Sean Faria
Prof. Bidot
BSC2085
M & W 7:05pm
Alzheimer’s disease:
A Deeper Look
Diana Vizoso
Samantha Concepcion
Melissa Sirolli
Sean Faria
BSC2085
M & W 7:05pm
Professor Bidot
Table of Contents
Page(s) #
Title Page.........................................................................................................................................2
Table of Contents.............................................................................................................................2
Causes..............................................................................................................................................4
Diagnosis..........................................................................................................................................9
Treatments......................................................................................................................................11
Index..............................................................................................................................................19
Bibliography..................................................................................................................................23
Reason
The reason my group choose this topic for our research paper is for three reasons. One
reason was the availability of information; it is easy to find information on the topic. Secondly
was the topic seemed very interesting because from the research we have collected at least two
people from this group will have Alzheimer’s disease as we age. Lastly was at least three of us
from the group have relatives with this disease and would like to know what at least is going on
so we may be some use to them. From this research paper we have learned a lot and this
Concept
Alzheimer’s disease is a brain disorder named for German physician Alois Alzheimer, who first
described it in 1906. Alzheimer's destroys brain cells, causing memory loss and problems
dementia include vascular dementia, mixed dementia, dementia with Lewy bodies and front
temporal dementia. The brain has 100 billion nerve cells (neurons). Nerve cell networks have
special jobs. In Alzheimer’s disease, as in other types of dementia, increasing numbers of brain
cells deteriorate and die. Plaques build up between nerve cells. Tangles form inside dying cells.
Scientists are not absolutely sure what role plaques and tangles play in Alzheimer’s disease.
Causes
Scientists are still trying to fully understand the cause or causes of Alzheimer’s disease.
In the meantime, it’s said to be helpful that we understand the hallmarks of Alzheimer’s plaques
and tangles and the risk factors that affect a person’s likelihood of developing the disease.
Alzheimer's disease is characterized by a build-up of proteins in the brain. Though this cannot be
measured in a living person, extensive autopsy studies have revealed this circumstance. The
build-up manifests in two ways. Plaques which are deposits of the protein beta-amyloid that
accumulates in the spaces between nerve cells. Another way this build up can occur is through
tangles, which are deposits of the protein tau that accumulate inside of nerve cells. Scientists are
still studying how plaques and tangles are related to Alzheimer’s disease.
One theory is that they block nerve cells’ ability to communicate with each other, making
it difficult for the cells to survive. It is likely that the causes include genetic, environmental, and
lifestyle factors, because people differ in their genetic make-up and lifestyle, the importance of
these factors for preventing or delaying AD differs from person to person. Autopsies have shown
that most people develop some plaques and tangles as they age, but people with Alzheimer’s
develop far more than those who do not develop the disease.
Scientists still don’t know why some people develop so many compared to others.
However, several risk factors for Alzheimer’s disease have been uncovered. Genetics play a role
in some people with AD. A rare type of AD, called early-onset AD, affects people ages 30 to 60.
Some cases of early-onset AD, called familial AD, are inherited. Familial AD is caused by
mutations (permanent changes) in three genes. Offspring in the same generation have a 50-50
Advancing age is the number one risk factor for developing Alzheimer’s disease. One out
of eight people over the age of 65 have Alzheimer’s disease, and almost one out of every two
people over the age of 85 has Alzheimer’s. Facts and studies show that the probability of being
diagnosed with Alzheimer’s nearly doubles every five years after age 65. People who have a
parent or sibling that developed Alzheimer’s disease are two to three times more likely to
develop the disease than those with no family history of Alzheimer’s. If more than one close
Scientists have identified two kinds of genes that are associated with this familial risk
factor. The first is thought to be a “risk gene,” ApoE 4, that increases the likelihood of
developing Alzheimer’s, but does not guarantee it. In addition to ApoE 4, scientists think there
could be up to a dozen more risk genes yet to be discovered. The second kind of gene is a
“deterministic gene” and is much rarer than risk genes. Deterministic genes are only found in a
If a deterministic gene is inherited, the person will undoubtedly develop Alzheimer’s, but
probably at a much earlier age. Although age and family history are out of our control, scientists
have also identified several lifestyle factors that can influence a person’s risk of developing
Alzheimer’s disease. A connection has been found between serious head injury and future
development of Alzheimer’s, so those who practice safety measures such as wearing seat belts
and not engaging in activities where there is a high risk of falling are at an advantage. Evidence
states that there should be a greater promotion of exercise and a healthy diet, to help reduce
Alzheimer’s risk.
Avoiding tobacco, limiting alcohol consumption, staying socially active, and engaging in
intellectually stimulating activities, have also been shown to have a protective effect against
Alzheimer’s disease. Finally, there is a strong link between heart health and brain health. Those
who are free of heart disease or related conditions are at a lower risk of developing Alzheimer’s
serious brain disorder that impacts daily living through memory loss and cognitive changes.
Some common signs of Alzheimer’s disease can be mixed up with normal everyday normality of
forgetfulness. Early stages of Alzheimer’s can be detected mainly by memory loss regarding
recent conversations and events. It can start off as routinely placing important items in odd
places, forgetting names of family members and common objects. It also is a result of, repeated
questions, forgetting the way to get to a frequent visited place and even the inability to following
simple directions for a recipe. This stage can usually last from 2-4 years.
Moderate to middle stage Alzheimer’s disease is usually discovered when they can no
longer cover up problems, have rambling speech, unusual reasoning, and have problems with
places and times. Constant reminders are needed; assistance is needed with daily living activities,
mood and behavioral changes start to occur and about 80% of patients show evidence of
emotional and behavioral problems which are aggravated by stress and change that they are not
Severe to Late stage Alzheimer’s is the result of confusion of the past and present.
Another sign is severe to total loss of verbal skills, they forget to speak or how to speak or write.
The person becomes completely incapable to care for self. They become very high risk to falling
due to gait dysfunction, and become bedridden. Patients begin to hallucinate, have severe mood
swings and behavioral issues. They tend moan and cry when unable to express what they are
feeling at the moment. They become totally dependent on others and need total support and care.
They can end up with issues such as the inability to swallow, incontinence, and illness. Illness is
the result of the body systems shutting down usually resulting in death. To sum up the basic
important information about Alzheimer’s disease one should the top ten basic signs to detect
Alzheimer’s.
First Sign is memory loss. We all experience it one way or another; it is just a matter of
knowing the difference between a slip-up and long-term forgetfulness. It is natural to forget an
appointment and/or a person’s name but to later remember it. Second basic sign of Alzheimer’s is
challenges arising when planning or solving problems. We can easily make a mistake while
balancing our check book every once in awhile but forgetting to pay monthly bills can be a sign
familiar tasks at home. Of course we forget what button to press when wanting to TiVo
something but forgetting the rules to your all time favorite board game, there’s obviously a
problem.
The fourth simple sign to detect Alzheimer’s disease is confusion time and place.
Obviously we can occasionally forget what day of the week it is but we always remember in the
end, whereas forgetting where we are and having no clue how we got there. These situations can
be very stressful. The fifth sign of Alzheimer’s is trouble understanding. Alzheimer’s prospect
begins having visual problems creating difficulty with reading. Over the years, with age, it is
common to be diagnosed with cataracts, which at this time would be natural to have difficulty
reading or seeing.
The sixth sign of Alzheimer’s is having trouble with speech i.e. speaking and writing. It
creates difficulty in joining in on conversations happening around them and or even while
they’re speaking they stop because they do not recall the subject of the conversation. We can be
in the middle of a conversation and be distracted by something but as long as we are reminded by
just a simple word. The seventh sign of Alzheimer’s is misplacing things and the inability to
retrace ones steps to remember. It’s normal for us to misplace the remote or even our car keys
time to time but to place our common everyday items in awkward places is a little sign of
Alzheimer’s.
The eighth sign of Alzheimer’s disease is decreased or poor judgment. It is normal for us
to every once in a while make bad decisions and Alzheimer’s prospects pay less attention to their
personal hygiene or can even pay people such as telemarketers large sum of money due to poor
judgment with money. The ninth sign of Alzheimer’s disease is withdrawal from work or social
activities. We are always at fault for feeling weary from work and wanting to be alone not having
Alzheimer’s prospect will begin to withdraw from their favorite hobbies and forget how their
favorite teams play. They can begin to feel that they don’t want to participate in anything
The final sign of Alzheimer’s is the change in mood and/or personality. The prospect can
become depressed, confused and even suspicious. We can usually create a routine of how we do
things and when they get interrupted we can become irritated and frustrated and it is perfectly
normal on occasion.
Diagnosis
Alzheimer’s disease causes physical change in a person’s brain that cannot be properly
diagnosed until being closely examined. Physicians are able to diagnose Alzheimer’s with 90%
accuracy due to thorough examination. Several of these medical examinations include the
patient’s history, a mini-mental state exam, specific laboratory testing, and certain neuro-imaging
examinations (Beers and Berkow). By gathering certain information from these exams, a doctor
can identify if a patient suffers from Alzheimer’s and what stage of Alzheimer’s the patient is
currently in.
For further explanation, a doctor will ask a series of questions to compose a medical
evaluation of the patient. The questions asked as part of the patients history includes information
of the problem occurring, a history of current illnesses, and any family history in regards to the
occurring problem. Physicians perform mini-mental exams that focus on the patient’s attention
span, memory and other types of mental moods. For instances, the doctor performing the exam
will try to interpret the different mood swings the patients undergoes. Another example would be
the attitude, behavior and appearance towards other people. Specialists evaluate patients on the
following statuses: Cognition, Insight judgment, Speech and language, Thought content, and
Thought processes.
After the physician has performed several mental tests, they usually send the patient to a
laboratory to have blood work done. Even though there is not a specific lab test that can identify
Alzheimer’s, the physician tries to rule out the possibility of other diseases by checking the
levels of certain chemicals in the body. Specialist analyze the levels of Vitamin B12, TSH (for
the thyroids), CBC (for anemia), and HIV. Furthermore, depending on the conditions of the
patient, the next step to evaluate if the patient has Alzheimer is to perform several neuro-imaging
exams. One of the main exams that a patient undergoes is a CT scan. A CT scan takes multiple
X-ray pictures of a certain body part to analyze any major changes. Patients with possible
Alzheimer’s carry out a CT scan of the brain, where specialist can observe changes in the size of
the brain. A size reduction of the brain may be a result of Alzheimer’s. Another imaging exam
will be an MRI, which shows the functional changes of the brain. MRI’s also rule out the
possibility of Alzheimer’s by observing if any tumors are present (Kasper, Braunwald and
Fauci). As stated previously, a patient cannot be properly diagnosed with Alzheimer’s until
further studies are done after the patient’s death. These are some of the methods to determine the
possibility of a patient suffering Alzheimer’s. There is only one method that has been recently
Treatments
Although no cure for Alzheimer’s disease is yet available, medical and behavioral
treatments for the disease may ease symptoms for the individual with Alzheimer's. The
symptoms that can be treated are the cognitive and behavioral symptoms. There is only three
ways for treating symptoms of Alzheimer’s. They are the Standard Treatments, Sleep Treatments
Standard Treatments consist of two types of medications that have been approved by the
U.S. Food and Drug Administration (FDA). The two types of drugs are cholinesterase inhibitors
and Memanatine. Cholinesterase inhibitors are prescribed to treat symptoms related to memory,
thinking, language, judgment and other thought processes. Three different cholinesterase
inhibitors are commonly prescribed. Donepezil also called Aricept, which is used to treat all
stages of Alzheimer’s disease. Galantamine also called Razadyne, used to treat mild to moderate
stages of Alzheimer’s. Rivastigmine also called Exelon, usually used to treat mild to moderate
Alzheimer’s. Tacrine also called Cognex, the first cholinesterase inhibitor, was approved in 1993
but is rarely prescribed today because of associated side effects, including possible liver damage.
with memory, judgment and other thought processes called acetylcholine. There are certain cells
in the brain that produce or release this chemical messenger acetylcholine, which in fact actually
help communicate between other cells. Upon this messenger reaching the receiving cell various
other chemicals as well as an enzyme called acetyl cholinesterase appear. This enzyme acetyl
However Alzheimer’s disease damages or worst yet destroys the cells that produce or use
acetylcholine. As a result of this process reduces the amount of acetylcholine to carry messages.
Cholinesterase inhibitor is actually an enzyme created to slow down the process of breaking
down the acetylcholine. Cholinesterase inhibitor accomplishes this by blocking the activity
acetyl cholinesterase. This process saves some acetylcholine from being destroyed by the
Alzheimer’s disease. These medications help the brain work better but it doesn’t stop or reverse
the destruction of the brain cells. Cholinesterase inhibitors do not prevent Alzheimer’s from
Galantamine appears to stimulate the release of acetylcholine and to strengthen the way certain
message-receiving nerve cells respond to it. Rivastigmine may block the activity of another
enzyme involved in breaking down acetylcholine. In contrast if side effects occur, they
commonly include nausea, vomiting, loss of appetite and increased frequency of bowel
medications monitor patients who are taking them, and that the recommended guidelines be
strictly observed.
language and the ability to perform simple tasks. This was the first Alzheimer drug of the NMDA
receptor antagonist type. Memanatine is used to treat moderate to severe Alzheimer’s only.
Memantine works by regulating the activity of a chemical involved in information
processing, storage and retrieval called glutamate. Perceptibly Glutamate triggers NMDA
receptors to let a controlled amount of calcium into a nerve cell as a result of this process it
significantly helps with learning and memory. The calcium helps creates the chemical
environment required for information storage. In the same way Glutamate can be helpful it can
be damaging. If there is excess Glutamate it over stimulates NMDA receptors so that they allow
too much calcium into nerve cells. In a nut shell excess glutamate causes disruption and death of
cells.
However Memantine may protect cells by partially blocking NMDA receptors. Adverse
side effects include headache, constipation, confusion and dizziness. Scientists have made
remarkable progress in understanding how Alzheimer’s affects the brain. Their insights point
toward promising new treatments to slow or stop the disease. Ultimately, the path to effective
The second treatment to help Alzheimer’s is sleep treatment. This is a significant factor
of Alzheimer’s because doctors have not found the exact reason why this happens. Many people
with Alzheimer’s experience changes in their sleep patterns. Similarly how Alzheimer’s affect
memory and behavior, sleep changes also occur to Alzheimer’s patients. There have been cases
of this in older adults without dementia who notice this as well. These conflicts occur more
frequently and tend to be more brutal in Alzheimer’s patients. This is common in later stages of
Alzheimer’s yet there have been reports and studies show to be found in the early stages as well.
This seems hard to believe that such a thing as difficulty sleeping can be caused by
Alzheimer’s. There are several patients with Alzheimer’s that wake up more often and stay
awake longer during the night. Brain wave studies have shown to have a decrease in both
dreaming and non-dreaming sleep stages. Sometimes those who can’t sleep may be unable to lie
Alzheimer’s patients have tendency for daytime napping and other shifts in the sleep-
wake cycle. Individuals may feel very drowsy during the day and then be unable to sleep at
night. Experts estimate that in late stages of Alzheimer’s, individuals spend about 40 percent of
their time in bed at night awake and a significant part of their daytime sleeping. Patients should
have a thorough medical examination to identify any treatable illnesses that may be contributing
to the sleeplessness. Some conditions are Depression, Restless legs syndrome, Sleep apnea.
Most doctors mostly try the non-drug treatment first due to the amount of medications
patients usually are taking. This treatment aspires to build a sleep routine, to decrease daytime
napping and to create the sleep environment necessary. The structure of this treatment consists of
Maintaining a schedule for regular times for meals and for going to bed and getting up,
Encourage regular daily exercise includes seeking morning sunlight exposure, Treat any pain,
Avoid alcohol, caffeine and nicotine, If the person is taking a cholinesterase inhibitor avoid
giving the medicine before bed, Make sure the bedroom temperature is comfortable, If the person
awakens, discourage staying in bed while awake; use the bed only for sleep, Discourage
The second Sleep treatment is obliviously medications. This is for the cases that non-
drug fails help the sleeplessness. There is one rule for delivering sleep medications all experts
agree on begin low and go slow. This rule came about because of the risk of sleep inducing
medication on older adults who are cognitively impaired are significant. The risks are increased
risk for falls and fractures, confusion, and a decline in the ability to care for oneself. However
once a sleep pattern has been established patients are too slowly discontinue them.
The most common used sleep medications are Tricyclic antidepressants, such as
nortriptyline and trazodone. Another is Benzodiazepines which common names are lorazepam,
oxazepam and temazepam. Sleeping pills also called zolpidem, zaleplon and chloral hydrate.
The final treatment is alternative therapy which consists of several herbal remedies,
vitamins and other dietary supplements. The safety and capability of these products are based
fundamentally on testimonials, tradition, and a rather small body of scientific research. The
reason this is called alternative therapy is due to the unknown. The effectiveness, safety, purity
are all unknown. The claims do not present enough evidence of effectiveness for FDA, as well as
FDA has no authority over supplement production. The safety of this therapy is also not
regulated. The safety precautions are actually given by healthcare professionals to the
manufacturers. Not to mention the risk of these products can have serious or serve interactions
protect nerve cells from certain kinds of chemical wear and tear. There is one large federally
funded study that shows that vitamin E can slightly slow down the loss of ability to carry out
daily life. Patients should not take vitamin E to treat Alzheimer’s unless supervised by physician.
The Vitamin E doses in these cases are relatively high. This high dose is why vitamin E should
never been taken without proper supervision. Vitamin E can interact with other medications,
was a synthetic version of this compound called idebenone, which was studied with Alzheimer’s
taken and considered safe. Consequently there can be harmful effects due to the lack of study.
Coral Calcium which is advertised as a cure for Alzheimer’s, cancer and other illnesses.
This is a form of calcium carbonate that is derived from shells of formerly living organisms that
made up coral reef. In June 2003, the Federal Trade Commission (FTC) and the Food and Drug
Administration (FDA) filed a formal complaint against the promoters and distributors of coral
calcium. Coral calcium differs from ordinary calcium supplements only in that it contains traces
of some additional minerals incorporated into the shells by the metabolic processes of the
Ginkgo biloba is a plant extract containing several compounds. Ginkgo biloba is thought
to have antioxidant and anti-inflammatory benefits that may have positive effects on cells within
the brain and the body. However, multicenter Phase III study published in the Journal of the
American Medical Association (November 19, 2008) proved that gingko was acting as a placebo
in delaying changes in memory, thinking and personality and had no impact on the development
of Alzheimer’s.
promoted as a treatment for Alzheimer's disease also may be comparable to approved drugs for
Alzheimer’s. There was a study for this drug launched in spring 2004 by no results has been
mentioned. This is also another drug that has been regulated as a dietary supplement with no
uniform standards. It is recommended not to be taken with prescribed medication due its
similarity to cholinesterase inhibitors and increase side effects of prescribed drug.
polyunsaturated fatty acid it has been more linked to heart disease and stroke than Alzheimer’s.
There are only two types of Omega-3’s qualified for use. Docosahexaenoic acid (DHA) and
Eicosapentaenoic acid (EPA) recently added to 75% of prenatal vitamins for develop of brain in
babies. This fatty acid cannot be made in the body this is fatty acid primarily use from fish oil or
flax oil. The reason why this was linked to the reduction of brain decline was that DHA is the
chief omega-3 in the brain. There are theories that Omega-3’s are might influence dementia risk
include their benefit for the heart and blood vessels, anti-inflammatory properties, and support
while protecting the nerve cell membranes. These findings are still under study and are in the
preliminary stage.
Index
in late middle age, characterized by memory lapses, confusion, emotional instability, and
progressive loss of mental ability. Named after Alois Alzheimer (1864–1915), German
4. Autopsy- inspection and dissection of a body after death, as for determination of the
messenger involved with memory, judgment and other thought processes called
acetylcholine.
variety of foods and synthesized in the body: sold as a dietary supplement for its
antioxidant properties.
7. Confusion- lack of clearness or distinctness: a confusion in his mind between right and
wrong.
8. Coral Calcium- This is a form of calcium carbonate that is derived from shells of
10. Depression- condition of general emotional dejection and withdrawal; sadness greater
11. Diagnose- to determine the identity of (a disease, illness, etc.) by a medical examination:
12. Dietary supplement- product taken orally that contains one or more ingredients that are
13. Docosahexaenoic acid (DHA)- an omega-3 fatty acid found especially in cold-water
fish.
14. Eicosapentaenoic acid (EPA)-An omega-3 fatty acid found in fish oils.
15. Fatty acid- any of a class of aliphatic acids, esp. palmitic, stearic, or oleic acid,
consisting of a long hydrocarbon chain ending in a carboxyl group that bonds to glycerol
to form a fat.
16. Federal Trade Commission (FTC)- A federal agency responsible for maintaining the
competitive markets, thereby discouraging restraint of trade and monopoly. The clout and
aggressiveness of the FTC vary greatly depending on its membership and the incumbent
Presidential administration.
17. Food and Drug Administration (FDA) - The FDA is responsible for protecting the
public health by assuring the safety, efficacy, and security of human and veterinary drugs,
biological products, medical devices, our nation’s food supply, cosmetics, and products
19. herbal remedies- a plant or plant part or an extract or mixture of these used to prevent,
20. Huperzine-A - is a moss extract usually used in traditional Chinese medicine. The
22. Memory- the mental capacity or faculty of retaining and reviving facts, events,
23. mild stages of Alzheimer’s- progress from mild forgetfulness to widespread neurological
25. Omega-3 - a polyunsaturated fatty acid, essential for normal retinal function, that
levels, inhibited platelet clotting, and reduced inflammatory and immune reactions.
26. Polyunsaturated fatty acid - an unsaturated fatty acid whose carbon chain has more
than one double or triple valence bond per molecule; found chiefly in fish and corn and
creeping sensations in them especially at night or when lying down and that is often
accompanied by insomnia and by involuntary twitching of the legs during sleep called
28. Serve stages of Alzheimer’s- is the result of confusion of the past and present. Another
sign is severe to total loss of verbal skills, they forget to speak or how to speak or write.
29. Sleep apnea- a temporary suspension of breathing, occurring in some newborns (infant
extend a whole.
31. Vitamin- any of a group of organic substances essential in small quantities to normal
32. Vitamin E- a pale-yellow viscous fluid, abundant in vegetable oils, whole-grain cereals,
butter, and eggs, and important as an antioxidant in the deactivation of free radicals and
Beers, Mark H. and Robert Berkow. "The Merck Manual of Diagnosis and Therapy, 17th
Edition." Delirium and Dementia. Whitehouse Station, New Jersey: Merck Research
Lon S. Schneider MD, (University of Southern California) reflects in the Journal of the
American Medical Association (JAMA. 2008;300[19] “Ginkgo Biloba and Alzheimer's
Kasper, Dennis L., et al. "Harrison's Principles of Internal Medicine, 16th Edition." Bird,
Thomas D. and Bruce L. Miller. Dementia. New York: McGraw-Hill Professional, 2004.
Chapter 365.
Appendix
A.1 – During the presymptomatic stage of Alzheimer's disease (A), a beta accumulates in diffuse plaques. Axons
and dendrites within and near the plaque appear structurally normal. By the symptomatic stage (B), many
plaques appear "mature”. Nearby microglia and astrocytes are activated, and axons and dendrites are
degenerating.